Highlights

  • Chimeric shares fell 20% to AUD 0.016 during the session.
  • The company ceased enrolment in its CHM-2101 Phase 1 clinical trial on 19 August.
  • Chimeric is redirecting its CDH17 development strategy towards an in-vivo approach.
  • Funding and development priorities are likely to remain central to the next phase.

Chimeric Therapeutics Ltd (ASX:CHM) has entered a new phase of its clinical development strategy following a major change to its CDH17 program.

CHM shares were trading at AUD 0.016, down 20%, giving the clinical-stage biotechnology company a Market Capitalisation of approximately AUD 0.98 million.

The share-price move comes days after a significant company update released on 19 August.

CHM-2101 Enrolment Comes to an End

Chimeric announced that it had ceased enrolment in the Phase 1 CHM-2101 clinical trial following dose-limiting toxicities.

The decision marked a change in direction for the company’s CDH17 development activities after the program had previously progressed through dose-escalation work.

Earlier in 2026, Chimeric had advanced the CDH17 trial to Dose Level 3 as it assessed the therapy across advanced gastrointestinal cancers.

The August update therefore shifted attention away from further enrolment in the existing Phase 1 study and towards Chimeric’s next technology approach.

Development Strategy Moves Towards In-Vivo CDH17

The company is now focusing on an in-vivo CDH17 strategy.

That transition changes the development path and places future technology validation, preclinical progress and funding requirements at the centre of the story.

Chimeric has also taken steps to lower its cost base, with the August update outlining approximately AUD 4 million in annualised cost reductions.

Earlier funding initiatives included an AUD 1.785 million advance against its FY26 Research and Development Tax Incentive and a broader funding package announced during FY26.

What Could Drive Chimeric Shares Next?

The company’s next catalysts are likely to be linked to its revised CDH17 development plan rather than the discontinued enrolment pathway.

Progress in the in-vivo program, capital availability and clarity around future clinical development will therefore be important.

For a clinical-stage biotechnology company, the pace of scientific advancement and ability to fund development remain closely connected.

Chimeric Therapeutics Outlook

Chimeric is reshaping its cell therapy portfolio following the CHM-2101 trial decision. The next phase will centre on advancement of its in-vivo CDH17 strategy, cost management and securing sufficient capital to progress its development priorities.